Xilio Therapeutics earnings were -$58.2M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest XLO earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$13.1M, down 6.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, XLO reported annual earnings of -$58.2M, with -23.8% growth. The next XLO earnings date is Jun 13, 2025.
What were Xilio Therapeutics's earnings last quarter?
Xilio Therapeutics (NASDAQ: XLO) reported Q4 2024 earnings per share (EPS) of -$0.18, up 71.88% year over year. Total XLO earnings for the quarter were -$13.09 million. In the same quarter last year, Xilio Therapeutics's earnings per share (EPS) was -$0.64.
The next XLO earnings date is Invalid Date. Add XLO to your watchlist to be reminded of Xilio Therapeutics's next earnings date.
Is Xilio Therapeutics profitable or losing money?
As of the last Xilio Therapeutics earnings report, Xilio Therapeutics is currently losing money. Xilio Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$58.24 million, a 23.77% decrease year over year.
What was XLO's earnings growth in the past year?
As of Xilio Therapeutics's earnings date in Q2 2025, Xilio Therapeutics's earnings has grown year over year. XLO earnings in the past year totalled -$58.24 million.
What are Xilio Therapeutics's earnings expectations?
The current EPS estimate for Xilio Therapeutics's earnings report in Invalid Date is -$0.11.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.